Kite adds industry veterans to leadership team

Kite Pharma has appointed two industry veterans to its leadership team as the Gilead company looks to strengthen its R&D efforts.

Charles Calderaro is joining as Global Head of Technical Operations, while Ken Takeshita has been appointed as Global Head of Clinical Development.

Mr Calderaro will be responsible for leading all aspects of Kite’s technical operations for the company’s commercial and pipeline products.

He joins from BioMarin Pharmaceutical where he currently holds the position of Senior Vice President of Global Manufacturing.

Previous, he was the Vice President of Technical Product Management at Genentech leading the CMC life cycle management of the company’s small molecule product portfolio in Basel, Switzerland.

Dr Takeshita will head Kite’s cell therapy clinical development organisation, including the company’s pipeline in solid tumour research.

He joins Kite from Sorrento Therapeutics, where he is currently Senior Vice President of Clinical Research, responsible for clinical development strategy in oncology.

His previous experience includes many years at Celgene Corporation, where he was Corporate Vice President for Clinical R&D and the Therapeutic Area Head for Lymphoma and CLL.

A message from the Editor:

Thank you for reading this story on our news site - please take a moment to read this important message:

As you know, our aim is to bring you, the reader, an editorially led news site but journalism costs money and we rely on advertising and digital revenues to help to support them.

With the Covid-19 lockdown having a major impact on our industry as a whole, the advertising revenues we normally receive, which helps us cover the cost of our journalists and this website, have been drastically affected.

As such we need your help. If you can support our news sites with a small donation of even £1, your generosity will help us weather the storm and continue in our quest to deliver quality journalism.

In the meantime may I wish you the very best.

- Advertisement -

First generic remdesivir for COVID-19 treatment launched

Beximco Pharmaceuticals, the Bangladesh-based manufacturer of generic pharma products and APIs, has launched the world’s first generic remdesivir for treating COVID-19. Remdesivir is an antiviral...

Vividion Therapeutics partners with Roche on novel E3 ligases

San Diego biotech, Vividion Therapeutics, is collaborating with Roche to leverage its proteomics screening platform and proprietary small molecule library to target novel E3...

Inovio publishes positive data on COVID-19 DNA vaccine

Inovio has published preclinical study data for IN0-4800 –  its COVID-19 DNA vaccine – demonstrating robust neutralising antibody and T cell immune responses against...

mRNA-based vaccine tech emerging as frontrunner against COVID-19

Messenger RNA (mRNA) based vaccine technology is emerging as one of the frontrunners among the technologies being evaluated to develop a vaccine for COVID-19,...

Tecentriq gains first-line approval in NSCLC

The FDA has approved Roche’s Tecentriq (atezolizumab) as a first-line monotherapy for the treatment of metastatic non-small cell lung cancer (NSCLC), marking its fourth...

Related news

Sinovac secures $15m to accelerate COVID-19 vaccine development

Sinovac Biotech, a Chinese biopharma product provider, has secured $15 million to accelerate the development of a COVID-19 vaccine. The funds were invested by Advantech...

First generic remdesivir for COVID-19 treatment launched

Beximco Pharmaceuticals, the Bangladesh-based manufacturer of generic pharma products and APIs, has launched the world’s first generic remdesivir for treating COVID-19. Remdesivir is an antiviral...

Vividion Therapeutics partners with Roche on novel E3 ligases

San Diego biotech, Vividion Therapeutics, is collaborating with Roche to leverage its proteomics screening platform and proprietary small molecule library to target novel E3...

Inovio publishes positive data on COVID-19 DNA vaccine

Inovio has published preclinical study data for IN0-4800 –  its COVID-19 DNA vaccine – demonstrating robust neutralising antibody and T cell immune responses against...